Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:NCEL NASDAQ:TPST NASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.91$1.84$1.26▼$4.50$16.27M2.411.05 million shs25,851 shsNCELNLS Pharmaceutics$3.23$3.15$1.83▼$30.80$17.28M0.9463,238 shs11,895 shsTPSTTempest Therapeutics$1.26$1.74$1.23▼$12.23$18.66M-1.8595,980 shs37,770 shsXTLBXTL Biopharmaceuticals$2.13$2.54$2.01▼$10.28$4.70M1.4819,559 shs8,563 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%-2.05%+12.35%+33.57%-24.21%NCELNLS Pharmaceutics0.00%+10.24%+0.62%+20.97%-85.83%TPSTTempest Therapeutics0.00%-0.79%-31.15%-42.99%-80.94%XTLBXTL Biopharmaceuticals0.00%+3.40%-18.39%-13.83%-89.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.91$1.84$1.26▼$4.50$16.27M2.411.05 million shs25,851 shsNCELNLS Pharmaceutics$3.23$3.15$1.83▼$30.80$17.28M0.9463,238 shs11,895 shsTPSTTempest Therapeutics$1.26$1.74$1.23▼$12.23$18.66M-1.8595,980 shs37,770 shsXTLBXTL Biopharmaceuticals$2.13$2.54$2.01▼$10.28$4.70M1.4819,559 shs8,563 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%-2.05%+12.35%+33.57%-24.21%NCELNLS Pharmaceutics0.00%+10.24%+0.62%+20.97%-85.83%TPSTTempest Therapeutics0.00%-0.79%-31.15%-42.99%-80.94%XTLBXTL Biopharmaceuticals0.00%+3.40%-18.39%-13.83%-89.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/ANCELNLS Pharmaceutics 1.00SellN/AN/ATPSTTempest Therapeutics 1.50ReduceN/AN/AXTLBXTL Biopharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, TPST, AIMD, and NCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026XTLBXTL Biopharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K135.61N/AN/A$1.29 per share1.48NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AXTLBXTL Biopharmaceuticals$968K4.85N/AN/A$2.47 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-160.55%-62.29%N/ANCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/ATPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)XTLBXTL Biopharmaceuticals-$1.03M-$0.64N/AN/AN/AN/AN/AN/AN/ALatest XTLB, TPST, AIMD, and NCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/AN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.580.550.50NCELNLS PharmaceuticsN/A0.760.76TPSTTempest TherapeuticsN/A0.740.74XTLBXTL BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ANCELNLS PharmaceuticsN/ATPSTTempest Therapeutics22.52%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%NCELNLS Pharmaceutics16.40%TPSTTempest Therapeutics36.30%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos408.52 million7.69 millionNot OptionableNCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableTPSTTempest Therapeutics2014.81 million9.43 millionNo DataXTLBXTL BiopharmaceuticalsN/A2.20 million1.57 millionNot OptionableXTLB, TPST, AIMD, and NCEL HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from NasdaqMay 23, 2026 | finanznachrichten.deXTL Announces Receipt of Staff Delist Determination from NasdaqMay 22, 2026 | globenewswire.comXTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital RaiseMay 15, 2026 | tipranks.comXTL Biopharmaceuticals Ltd ADR XTLBMay 14, 2026 | morningstar.comMXTL Biopharmaceuticals Delays 20-F Amid Subsidiary LiquidationMay 3, 2026 | theglobeandmail.comXTL Biopharmaceuticals Ltd.May 1, 2026 | marketwatch.comWashington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a KeyMay 1, 2026 | theglobeandmail.comXTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the tableMay 1, 2026 | msn.comXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...April 29, 2026 | markets.businessinsider.comXTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growthApril 29, 2026 | msn.comXTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcementApril 29, 2026 | quiverquant.comQXTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug PipelineApril 29, 2026 | tipranks.comXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin TechnologiesApril 29, 2026 | globenewswire.comXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio ChangeMarch 21, 2026 | finanznachrichten.deXTL Biopharmaceuticals Announces ADS Ratio ChangeMarch 20, 2026 | globenewswire.comXTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI ExpiresMarch 10, 2026 | tipranks.comXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request HearingFebruary 28, 2026 | finanznachrichten.deXTL Biopharmaceuticals stock falls on Nasdaq delisting noticeFebruary 27, 2026 | investing.comXTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social ProxyFebruary 27, 2026 | quiverquant.comQXTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request HearingFebruary 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, TPST, AIMD, and NCEL Company DescriptionsAinos NASDAQ:AIMD$1.91 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.84 -0.08 (-3.93%) As of 06/12/2026 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.NLS Pharmaceutics NASDAQ:NCEL$3.23 0.00 (0.00%) As of 06/12/2026 03:22 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Tempest Therapeutics NASDAQ:TPST$1.26 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.26 +0.00 (+0.40%) As of 06/12/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.XTL Biopharmaceuticals NASDAQ:XTLB$2.13 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.04 -0.09 (-4.18%) As of 06/12/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
